tbuckley/cabot-search huggingface dataset:
A new prognostic index of advanced epithelial ovarian cancer (PIEPOC): A JMTO OC01–01 study
Authors: S. Teramukai, K. Ochiai, H. Tada, M. Fukushima
Journal: Journal of Clinical Oncology (2006)

5061 Background: The prognostic factors in patients with advanced epithelial ovarian cancer (EpOC) have been identified by many investigators. The purpose of this study was to construct a simple and powerful prognostic index (PI) of EpOC (PIEPOC) by using data from a long-term follow-up study. Methods: Data from 768 women with stage III or IV EpOC from 24 institutions in Japan who were treated between 1994 and 2000 were evaluated for clinical features predictive of overall survival. A PI to predict overall survival after initial surgery was developed using proportional hazards regression model. We selected the best classification in an attempt to separate the prognosis of patients. Results: Out of 768 patients, 408 patients were died and a median follow-up for 360 surviving patients was 4.2 years. We randomly selected 538 (70%) patients as a training sample set. The four prognostic factors that remained independently significant in the analysis of the training sample were age, performance status (PS), cell type, and size of residual disease. After combining levels of factors that appeared to have a similar effect on survival and checking additivity of effects by pooled interaction tests, a linear function based on estimated regression coefficients was as follows: 0.448 (if age 70 and above) + 0.539 (if PS 1 or 2) + 0.980 (if PS 3 or 4) + 0.488 (if mucinous or clear cell) + 0.943 (if residual size 0.1cm and above). From the weight of function, we derived a simplified PI (PIEPOC) = 1 (if age 70 and above) + 1 (if PS 1 or 2) + 2 (if PS 3 or 4) + 1 (if mucinous or clear cell) + 2 (if residual size 0.1 cm and above). The PIEPOC of patients were distributed between 0 and 6. Patients were classified into three risk groups, i.e., low (PI: 0–2), intermediate (PI: 3), and high (PI: 4–6). The PIEPOC was equally predictive in a randomly selected validation sample set (n = 230), identifying three groups (5-year survival: 0.67 in low, 0.43 in intermediate, 0.17 in high risk group, respectively). This predictability was reproducible in Stage IIIc or IV patients. Conclusions: Our PIEPOC is simple and easy to use to discriminate the risk groups among advanced EpOC. Thus PIEPOC should be useful for the selection of appropriate treatment options. No significant financial relationships to disclose.
Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,
Authors: Erica Evans, Richland Tester, Sharon Aslanian, Prasoon Chaturvedi, Hormoz Mazdiyasni, Sabine Ponader, Bethany Tesar, Michael Sheets, Mariana Nacht, Kathryn Stiede, Steve Witowski, Heather Lounsbury, Russell Petter, Jennifer R. Brown, Jan A. Burger, Juswinder Singh, William F. Westlin
Journal: Blood (2011)
RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival
Authors: T. Buanes, S. Bernhardt, K. Lislerud, I. Gladhaug, M. Moeller, J. A. Eriksen, G. Gaudernack
Journal: Journal of Clinical Oncology (2007)

4543 Background: K-RAS mutations are found in most adenocarcinoma of the pancreas, and targeting mutant RAS by vaccination may be of clinical importance. The present follow-up study was performed to determine whether or not mutant RAS specific T cells were still present in long term survivors seven to nine years after postoperative adjuvant vaccination with synthetic mutant RAS peptides Methods: During 1995–98, all together 23 patients were recruited into two clinical studies. The patients in CTN95002 (n = 10) were given a single mutant RAS peptide (100μg) corresponding to the RAS mutation identified in the patient’s tumor. Patients in CTN98010 (n = 13) were given a mixture of seven mutant RAS peptides, (700μg), corresponding to the most common mutations in pancreatic adenocarcinoma, in a 10 week vaccination regimen, using GM-CSF as an adjuvant, and boosters for an extended period. Immune responses were measured as skin reaction (DTH) and/or in vitro T-cell response. Blood samples from the five patients, still alive in 2006, were investigated by in vitro T-cell proliferation assay for immunological memory. Results: The five surviving patients were all immune responders during the primary vaccination period. Analysis of T-cell reactivity was performed seven (one patient), eight (one patient) and nine years (three patients) after resection/vaccination. Three patients still showed immune responses against the vaccine given previously. T cell reactivity against the Gly12Val mutation was observed in one patient receiving this peptide. In another patient a strong T cell reactivity against all seven peptides present in the vaccine, was observed. Conclusions: Long term survival beyond seven to nine years was only found in patients who primarily responded immunologically on the RAS-vaccination. Long term immunological memory can be induced by peptide vaccination. No significant financial relationships to disclose.
Laparoscopic radiofrequency ablation and systemic chemotherapy for colorectal liver metastases
Authors: D. A. McCain
Journal: Journal of Clinical Oncology (2004)

3776 Background: Evaluation of 38 patients with colorectal liver metastases(164 lesions) from 11/2000 to12/2003 treated with systemic chemotherapy and laparoscopic radiofrequency ablation. Methods: All patients were treated with standardized systemic regimens of 5-FU, irinotecan and oxaliplatinum with laparoscopic radiofrequency ablation. Results: Median follow up was 16 months (range 3–36 months) with a 78.6% survival at 16 months. Survival by Kaplan-Meier actuarial survival analyis was 84.7% at 1 year and 52.3% at two yearswith improved disease free survival seen in patients with lesions <5cm in size and < 5 in number. Conclusions: Laparoscopic radiofrequency ablation was safe and effective when combined with systemic chemotherapy in treating colorectal liver metastases with patients being able to maintain their chemotherapy treatment schedules. Patients with low volume disease had the highest survival benefit. No significant financial relationships to disclose.
Colorectal cancer susceptibility variants and clinical outcome in adjuvant and metastatic colorectal cancer
Authors: H. Lenz, G. Lurje, C. A. Haiman, D. Yang, A. Pohl, Y. Ning, A. El-Khoueiry, S. Iqbal, W. Zhang
Journal: Journal of Clinical Oncology (2009)

4051 Background: Recent genome-wide association studies had identified colorectal cancer susceptibility loci on chromosomes 8q24 (rs6983267), 15q13(rs4779584), 18q21(rs4939827, rs12953717 and rs4464148), 10p14(rs10795668) and 8q23.3(rs16892766). Although the function role of these germline variants are unclear, given the importance of these variants and colorectal cancer risk, we have carried out the first pilot study to explore the association of these variants and clinical outcome. We used pooled data from two CRC-cohorts (locally advanced and metastatic CRC), and investigated the hypothesis that these germline variants may be associated with clinical outcome in adjuvant and metastatic colorectal cancer patients. Methods: Whole blood was collected from 515 patients with locally advanced (n=197) and metastatic CRC (n=318). After extraction of genomic-DNA, germline variants were genotyped as previously described (Haiman et al, Nat Genet, 2007). The genotype success rate was 98%. Blinded repeat samples (5%) were included for quality control purposes; genotype concordance was ≥ 99%. Results: Our results suggest that rs10795668 at 10p14 and rs719725 are significantly associated with time to tumor recurrence in adjuvant colorectal cancer patients, patients with rs10795668 AA genotype had significantly increased risk of time to tumor recurrence compared with those harboring G allele (TG+GG) patients(p=0.05, log-rank test). In metastatic cancer patients, we found rs4939827 at 18q21.1 were significantly associated with overall survival in female patients and rs10795668 at 10p14 were significantly associated with OS in male patients, respectively (p&lt;0.05). Conclusions: Our preliminary results suggest cancer risk alleles may also associated with clinical outcome in adjuvant and metastatic colorectal cancer. Moreover, this correlation is sex-specific in metastatic colorectal cancer. Further comprehensive trials warranted to confirm our pilot findings. [Table: see text]
Response to: ‘Remission in systemic lupus erythematosus: durable remission is rare’ by Wilhelm<i>et al</i>
Authors: Mandana Nikpour
Journal: Annals of the Rheumatic Diseases (2016)

We read with interest the article by Wilhelm et al , reporting the frequency, durability and predictors of four definitions of remission, agreed upon by an international groups of experts (Definition of Remission in Systemic Lupus Erythematosus (SLE); DORIS, in the Baltimore lupus cohort.1

As the premise of defining remission is to provide a therapeutic target to guide the management of SLE, we question the value of having four definitions. We further argue that the complete absence of clinical disease activity off of all treatment may simply identify a small group of patients who inherently have a less severe disease …
Treatment Outcomes for Imatinib Mesylate and Allogeneic Stem Cell Transplantation in Patients with CML Based on RQ-PCR, and the Efficacy of Dose Escalation of Imatinib Mesylate in Patients with Cytogenetic or Hematologic Resistance.
Authors: Sang Kyun Sohn, Yoon Young Cho, Byung Min Ahn, Yee Soo Chae, Jong Gwang Kim, Joon Ho Moon
Journal: Blood (2006)
GW26-e4459 Cellular Electrophysiological Mechanisms and Drug Intervention Study of the CACNA1C Gene Mutation Related to Early Repolarization
Authors: Xin Liu, Yang Shen, Qing Cao, Jinyan Xie, Ping Yuan, Wei Lai, Xiaogang Peng, Rong Wan, Kui Hong
Journal: Journal of the American College of Cardiology (2015)
Beyond the Gatekeeper: Imatinib- and Dasatinib-Resistant BCR-ABL/F317 Mutations Confer Cross-Resistance to VX-680 but Are Sensitive to a Structural Derivative of VX-680
Authors: Corynn Kasap, Nicholas Hertz, Debora Makino, Kevan Shokat, John Kuriyan, Neil P. Shah
Journal: Blood (2008)
R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.
Authors: Alden A. Moccia, Kimberly Schaff, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn
Journal: Blood (2009)
Maintenance Therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.
Authors: Philippe Rousselot, Françoise Huguet, Norbert Vey, Kamal Bouabdallah, Jacques Delaunay, Sébastien Maury, Felipe Suarez, Francis Witz, Martine Escoffre-Barbe, Cécile Fohrer, Sophie Rigaudeau, Pascal Turlure, Bernard Rio, Jean Pierre Marolleau, François Guilhot, Magda Alexis, Sélim Corm, Bruno Audhuy, Oumedaly Reman, Sylvie Caillières, Hervé Dombret, Jean Michel Cayuela
Journal: Blood (2007)
The Biomarkers Consortium: A public-private partnership of the Foundation for NIH
Authors: D. Lee, T. Altar
Journal: Journal of Clinical Oncology (2007)

14142 Background: In October 2006, the Foundation for the National Institutes of Health (FNIH) announced the launch of a major public-private biomedical research partnership, The Biomarkers Consortium, to search for and validate new biological markers-biomarkers- to accelerate dramatically the delivery of successful new technologies, medicines, and therapies for prevention, early detection, diagnosis, and treatment of disease. The Foundation for NIH is managing The Biomarkers Consortium under direction of the consortium executive committee, with guidance from leading scientists within and outside the member organizations, plus input from a public representative and private industry and non-profit funding partners. FNIH, CMS, FDA, NIH, and the pharmaceutical, biotechnology, diagnostics, and medical device industries recognize the critical need for a coordinated cross-sector partnership effort to more rapidly identify and qualify biomarkers to support basic and translational research, guide clinical practice and, ultimately, support the development of safe and effective medicines and treatments for a wide range of diseases. The Biomarkers Consortium will harmonize approaches to identifying viable biomarkers, verifying their individual value, and formalizing their use in research and regulatory approval. Information and results from consortium projects will be used broadly by researchers to promote the appropriate use of biomarkers to improve the public health worldwide. Methods: N/A Results: Promising project concepts that have been approved in principle for further development by The Biomarkers Consortium include the Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) Lung Cancer and Non-Hodgkin’s Lymphoma Projects and projects in metabolic disorders and neuroscience. Steering Committees in cancer, metabolic disorders, and neuroscience have been created to evaluate and develop project concepts approved for further development. Conclusions: The Biomarkers Consortium is an important avenue to facilitate the search and validation of a variety of biomarkers projects. No significant financial relationships to disclose.
Prognostic factors of the loss of autonomy (LoA) in older patients with cancer receiving first-line chemotherapy.
Authors: Pierre-Louis Soubeyran, Marianne Fonck, Laurent Hoppenreys, Stephanie Hoppe, Carine Bellera, Christele Blanc-Bisson, Jean-Frédéric Blanc, Joel Ceccaldi, Cecile Mertens, Yves Imbert, Laurent Cany, Luc Vogt, Jérôme Dauba, Nadine Houede, Anne Floquet, François Chomy, Veronique Brouste, Alain Ravaud, Simone Mathoulin-Pelissier, Muriel Rainfray
Journal: Journal of Clinical Oncology (2012)

9012 Background: Actual data on prognostic geriatric factors of health outcomes are lacking. We aimed to examine whether a decrease in autonomy for activities of daily living (ADL) after a first cycle of chemotherapy influences elderly cancer pts prognosis, and to determine prognostic factors of this LoA from a range of biological and geriatric evaluation factors. Methods: Pts&gt; 70 years receiving 1st-line chemotherapy for a range of cancers were included in this multicentre prospective study. A LoA was defined as a decrease of 0.5 or more points on the ADL scale between the beginning of treatment and the 2nd cycle (ADL scored 6 to 0). The association between a LoA and OS was examined and prognostic factors were sought from the pre-treatment Geriatric Assessment data (CIRS-G, IADL, MNA, MMSE, GDS et Get up and Go) and from baseline biological and clinical information (age, sex, tumor extension and localization, performance status, BMI, weight loss, albumin, CRP, haemoglobin levels, leucocyte and platelet count, creatinine clearance). Pts completely dependent at baseline (ADL score 0) were excluded as a LoA was not possible. Results: Among 364 pts included, 299 pts were evaluable and 50 experienced a LoA. A LoA was significantly associated with an increased risk of death (RR 1.518, 95%CI[1.079-2.135]). Biological and clinical factors were not associated with LoA but pre-treatment low GDS15, dependencies on the IADL, low MMS, slow Get Up and Go, low ECOG-PS and poor MNA were found to be prognostic of a LoA in univariate analyses. In the multivariate model, low GDS (OR 2.4, p=0.01, 95%CI [1.23-4.66]) and dependencies on the IADL (OR 3.0, p= 0.027, 95%CI = [1.13-9.09]) were independently associated with an increased risk of LoA. Conclusions: Our study underlines the close link between LoA during treatment and poorer prognosis of elderly pts with cancer. Pts with a pre-treatment low GDS15 and IADL-dependent were the most likely to experience LoA after the 1st chemotherapy cycle. This research suggests that the GDS15 and IADL should be included as part of any screening for elderly pts before treatment.
Late Onset Neutropenia and Decreased Immunoglobulin Concentration after Rituximab Combined Autotransplantation for B Cell Lymphoma.
Authors: Yasuo Hirayama, Kyuhei Kohda, Yasuji Hirata, Hiroyuki Kuroda, Takuya Matsunaga, Yuichi Konuma, Makoto Yoshida, Toshiro Sakai, Yoshiro Niitsu
Journal: Blood (2005)
Adjuvant Folfox4 Plus or Minus Cetuximab (CMAB) in Patients (PTS) with Kras Mutant (MKRAS) Resected Stage III Colon Cancer (CC). Results from the PETACC8 Intergroup Trial
Authors: R. Salazar, E. Mini, G. Folprecht, F. Subtil, J. van Laethem, J. Thaler, J.A. Bridgewater, E. Van Cutsem, C. Lepage, J. Taieb
Journal: Annals of Oncology (2012)
Hunt denies that NHS efficiencies mean inevitable rationing
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Tough efficiencies in the health service can be made without damaging patient care, England’s health secretary has said, despite recent warnings that rationing of services will become inevitable without extra money.

Jeremy Hunt, appearing before the parliamentary health committee on 18 October during an evidence session for its inquiry into the current state of NHS finances, denied that the NHS was in a perilous state but admitted that finances were challenging.

“I don’t believe at all that the NHS is awash with cash, and there are very real financial pressures as the NHS copes with the extraordinary pressures on the front line, particularly to do with the ageing population,” he told MPs.

However, he denied the extent of the problems as set out by previous witnesses to the inquiry, such as the representative bodies NHS Providers and NHS Clinical Commissioners—namely, that without extra funding, choices would have …
Balance of Transcription Factors Downstream of Notch Signaling Determines the Fate of Myeloid Progenitors toward Differentiation to Mast Cells or Immortalization without Differentiation.
Authors: Mamiko Sakata-Yanagimoto, Fumio Nakahara, Etsuko Yamaguchi-Nakagami, Keiki Kumano, Toshiki Saito, Mineo Kurokawa, Seishi Ogawa, Shigeru Chiba
Journal: Blood (2006)
The needs and experiences of patients with skin cancer: a qualitative systematic review with metasynthesis
Authors: F. Bath‐Hextall, S. Nalubega, C. Evans
Journal: British Journal of Dermatology (2016)

Skin cancer incidence is increasing worldwide. This is an update of a previous review published in 2010 that identified only two studies and found that the needs and experiences of individuals with skin cancer were under‐researched. Our objective was to undertake a qualitative systematic review of the needs and experiences of people with a diagnosis of skin cancer. To update the previous review, the following databases were searched from 2010 to 30 November 2015: CINAHL PsycINFO, Medline and Embase. The methodological quality of the studies was assessed using the Joanna Briggs Institute Qualitative Assessment Review Instrument. The qualitative research findings were synthesized using a pragmatic meta‐aggregative approach. A total of 14 studies (16 papers) were included. Only three studies included patients with keratinocyte carcinoma. Overall, 15 categories were identified and these resulted in four overarching synthesized findings (SFs) from diagnosis (SF1), throughout treatment (SF2) and follow‐up (SF3), and then a fourth SF (SF4) that addressed patients' satisfaction with their care and their relationship with healthcare professionals. Despite the fact that patients with keratinocyte carcinoma and melanoma can have a very different prognosis, they also share similar needs and concerns especially around the time of diagnosis and follow‐up/surveillance for new lesions. Healthcare professionals working with patients with skin cancer need to understand their psychosocial concerns and their information needs in order to design services appropriately. Future studies need to consider patients with keratinocyte carcinoma in addition to patients with melanoma.
Assessing the Effect of the Affordable Care Act on Surgical Populations
Authors: Hari Nathan, Justin B. Dimick
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P0543 : Comparative evaluation of the artus HBV QS-RGQ assay and the roche cobas mpliprep/cobas taqman V.2 HBV test for the quantification of HBV DNA in plasma
Authors: S. Brichler, S. Dziri, A. Duhant, G. Faleu, E. Gordien
Journal: Journal of Hepatology (2015)
Cytogenetic Findings and Pattern of Clonal Evolution Determine Survival in Patients with Primary or Secondary Myelofibrosis
Authors: Constantine S. Tam, Lynne V. Abruzzo, Katherine I. Lin, Jorge Cortes, Alice Lynn, Michael J. Keating, Deborah A. Thomas, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2007)